THE FIRM PROFESSIONALS
IMAMURA, Masazumi Partners
Managing Equity Partner
Member of Pharmaceutical Society of Japan
Passed national examination for pharmacists (not registered)
Registered as a patent attorney in April 1988
Patent Attorney Registration No. 9621
Areas of expertise
A61KC07B (excluding devices)C07CC07DC07FC07GC07HC07JC07KC12N 5/00
In particular: Pharmaceutical chemistryPharmaceutical technochemistryPharmacologyGalenical pharmacyOrganic chemistryBiochemistryRegenerative medicineBiopharmaceuticalsandHuman undifferentiated cells
Education
March 1979: Bachelor of Science in Pharmaceutical Chemistry, The University of Tokyo
March 1981: Master of Pharmaceutical Chemistry, Graduate School of Medicine, The University of Tokyo
Professional background
April 1981: Joined Daiichi Pharmaceutical Co., Ltd. (currently Daiichi-Sankyo Co., Ltd.)
April 1988: Joined Nakamura & Partners
April 1988: Registered as a patent attorney (passed examination for patent attorney in 1987)
August 1993: Became a partner of SIKs & Co.
January 2004: Registered as specific infringement lawsuit counsel as provided in supplementary note
Achievements as member and lecturer
April 2004 to March 2005: Expert Committee Member Affiliated with Tokyo High Court (Part Time Court Official)
April 2005 to March 2020: Expert Committee Member Affiliated with Intellectual Property High Court (Part Time Court Official) (two-year tenure, eight consecutive terms)
Professional background
Engaged in exploratory research of quinolone-based synthetic antibacterial agents in Daiichi Pharmaceutical Co., Ltd. (currently Daiichi-Sankyo Co., Ltd.) Central Research Laboratory, and is a joint inventor of Japanese Patent No. 1659502 “Pyridobenzoxazine derivatives” pertaining to “Cravit”, which is the company’s core product. Joint inventor in each of the following patents in the research conducted by the foregoing Laboratory: Japanese Patent No. 3026162 “Spiro compound” (inventor) Japanese Patent No. 2978490 “5-substituted-4,7-dioxo-5-azaspiro [2.4] heptane derivatives” Japanese Patent No. 2978491 [7-amino-5-substituted-5-azaspiro [2.4] heptane derivatives” Japanese Patent No. 2807277 “Spiro compound” Japanese Patent No. 2520549 “fluorocyclopropyl aminoacrylic acid ester derivatives” Japanese Patent No. 2532192 “1-amino-2-fluorocyclopropyl” Japanese Patent No. 2106444 “1-(2-halegenocyclopropyl) quinolinecarboxylic acid derivatives” Japanese Patent No. 1979790 “Pyridobenzoxazines” Japanese Patent No. 2008845 “Pyridobenzoxazine derivatives” Japanese Patent No. 1853582 “1-(2-halegenocyclopropyl) quinolinecarboxylic acid derivatives”
Patent agent
Drafted patent specifications for the Japanese application (Japanese Patent Application No. 2005-359537) and the PCT application (PCT/JP2006/324881) related to the pioneer invention of iPS cells of Professor Shinya Yamanaka of Kyoto University, served as the patent agent of these applications, and took measures for obtaining the basic patent (Patent No. 4183742)
Contentious cases
Counsel in appeal case (2004 (ju) Case No. 997, Law Report Vol. 59, No. 5, p. 1074) pertaining to the Supreme Court Decision which acknowledged the right to demand an injunction of the patentee that established an exclusive license Counsel in appeal case (2012 (ju) Case No. 2658, Law Report Vol. 69, No. 4, p. 904) pertaining to the Supreme Court Decision which rendered judgment on the definiteness requirement regarding product-by-process claims Counsel in appeal case (2015 (ne) Case No. 10014) pertaining to the Intellectual Property High Court Grand Panel Case related to the infringement under the doctrine of equivalents Counsel in appeal case (2016 (ju) Case No. 1242, Law Report Vol. 71, No. 3, p. 359) pertaining to the Supreme Court Decision which rendered judgment on the fifth requirement under the doctrine of equivalents Counsel in case seeking revocation of trial decision (2016 (gyo ke) Case No. 10182) pertaining to the Intellectual Property High Court Grand Panel Case related to the benefit of suit